Is the current evidence in support of percutaneous coronary intervention for the treatment of unprotected left main stem disease?  Current guidelines indicate coronary artery bypass grafting is the standard of care.  Should the use of drug-eluting stents in “off-label” cases be discouraged and good surgical candidates with unprotected left main coronary artery disease undergo surgical revascularization?  Is CABG really proven to perform better than PCI in this subset of patients and is CABG to be recommended in all good surgical candidates? 

The current status of Drug Eluting Stents will be debated and addressed in Cross Fires with Surgeons, Cardiologists and Interventional Cardiologists at the World Renowned “Controversies and Advances in the Treatment of Cardiovascular Disease: The Eighth in the Series” symposium to be held September 4-5, 2008 in Beverly Hills, California.